This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Has OPKO Health (OPK) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (OPK) Outperforming Other Medical Stocks This Year?
Neogen (NEOG) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Neogen's (NEOG) Animal Safety revenues improve in the fourth quarter on strong sales of cleaners, disinfectants and sanitizers.
Thermo Fisher (TMO) Q2 Earnings Beat on COVID-19-Led Sales
by Zacks Equity Research
We are encouraged about Thermo Fisher's (TMO) exceptionally strong year-over-year revenue growth at Life Sciences Solutions segment.
Intuitive Surgical (ISRG) Q2 Earnings Top Estimates, Down Y/Y
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results reflect weak performance across all businesses and lower revenues.
AngioDyanamics (ANGO) Reports Q4 Loss, Revenues Lag Estimates
by Zacks Equity Research
AngioDyanamics (ANGO) witnessed revenue decline across all business segments in Q4.
Abbott (ABT) Q2 Earnings Top, Coronavirus Test Sales Solid
by Zacks Equity Research
Abbott (ABT) Q2 earnings reflect healthy growth within its Diabetes Care business and encouraging coronavirus test sales.
Implied Volatility Surging for OPKO Health (OPK) Stock Options
by Zacks Equity Research
Investors need to pay close attention to OPKO Health (OPK) stock based on the movements in the options market lately.
OPKO Health (OPK) Flat As Market Gains: What You Should Know
by Zacks Equity Research
OPKO Health (OPK) closed the most recent trading day at $4.02, making no change from the previous trading session.
Why OPKO Health (OPK) Stock Might be a Great Pick
by Zacks Equity Research
OPKO Health (OPK) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Here's Why You Should Invest in OPKO Health (OPK) Stock Now
by Zacks Equity Research
OPKO Health (OPK) continues to benefit from lucrative prospects in RAYALDEE and BioReference platforms.
Is OPKO Health (OPK) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (OPK) Outperforming Other Medical Stocks This Year?
OPKO Health's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in OPKO Health.
Is OPKO Health (OPK) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (OPK) Outperforming Other Medical Stocks This Year?
Is the Options Market Predicting a Spike in OPKO Health (OPK) Stock?
by Zacks Equity Research
Investors need to pay close attention to OPKO Health (OPK) stock based on the movements in the options market lately.
OPKO Health (OPK) Up 16.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Company News for June 2, 2020
by Zacks Equity Research
Companies in the news are: MYOV, ITRM, COTY, OPK
OPKO Health (OPK) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
OPKO Health (OPK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Has OPKO Health (OPK) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (OPK) Outperforming Other Medical Stocks This Year?
Here's Why You Should Invest in OPKO Health (OPK) Stock Now
by Zacks Equity Research
OPKO Health (OPK) continues to gain traction from solid prospects in RAYALDEE and BioReference platforms.
How OPKO Health (OPK) Stock Stands Out in a Strong Industry
by Zacks Equity Research
OPKO Health (OPK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Why OPKO Health (OPK) Could Be Positioned for a Surge
by Zacks Equity Research
OPKO Health (OPK) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors
Moving Average Crossover Alert: OPKO Health
by Zacks Equity Research
OPKO Health, Inc. (OPK) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
OPKO's BioReference Laboratories' Deal Brings Antibody Testing
by Zacks Equity Research
OPKO Health's (OPK) subsidiary, BioReference Laboratories collaborates with MagnaCare to offer antibody testing to Labor groups in New York metropolitan area.
Are Options Traders Betting on a Big Move in OPKO Health (OPK) Stock?
by Zacks Equity Research
Investors need to pay close attention to OPKO Health (OPK) stock based on the movements in the options market lately.
OPKO Health, Inc. (OPK) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in OPKO Health, Inc. (OPK).